FDA Broadens Anktiva Treatment Approval for Specific Bladder Cancer Patients

The U.S. Food and Drug Administration has expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG. This updated indication now covers adults with BCG-unresponsive non-muscle invasive bladder cancer, specifically those with high-grade, papillary-only tumors. This action provides new treatment options for a distinct group of bladder cancer patients.